EGFR and non-small cell lung carcinoma: Several third‐generation EGFR‐TKIs were designed to selectively and irreversibly target both the original EGFR‐sensitive mutations and the sequential EGFR T790M mutation, such as osimertinib (AZD9291),4 aumolertinib (almonertinib; HS‐10296),5 avitinib (abivertinib; AC0010),6 and so on, which have become the frontline and second‐line therapy for advanced EGFR‐mutant NSCLC.